Bayesian Design for Pediatric Clinical Trials with Binary Endpoints When Borrowing Historical Information of Treatment Effect

被引:0
|
作者
Man Jin
Qing Li
Amarjot Kaur
机构
[1] Biostatistics and Research Decision Sciences,
[2] MRL,undefined
[3] Merck & Co.,undefined
[4] Inc.,undefined
[5] AbbVie Inc.,undefined
关键词
Sample size calculations; Bayesian framework; Prior distributions; Hierarchical model; Pediatric clinical trials;
D O I
暂无
中图分类号
学科分类号
摘要
The efficacy evaluation in pediatric population is an important component of drug development and is generally required by the regulatory agencies. It is often challenging to enroll pediatric subjects for a large trial especially when the incidence rate is low in certain disease areas. Bayesian framework can provide analytic avenues to effectively utilize historical information of the treatment effect and help make pediatric trials more efficient by reducing the sample size when there is evidence to suggest similarity of the treatment responses between the populations. Schoenfeld et al. (Clin Trials 6(4):297–304, 2009) proposed a Bayesian hierarchical model for efficacy extrapolation for continuous endpoints, which connects a single historical trial and the current trial by a variance parameter in the prior distribution. In this manuscript, we extend the existing model to borrow strength from multiple historical trials under the same assumptions and develop a quantitative method to borrow historical information more efficiently. Furthermore, we extend Schoenfeld’s method based on continuous endpoints to binary endpoints with a hierarchical binomial model to extrapolate efficacy. Sensitivity analyses for the underlying assumptions are discussed with simulations and the methods are illustrated with a real case study, along with some practical considerations about how to choose the prior distribution.
引用
收藏
页码:360 / 369
页数:9
相关论文
共 50 条
  • [41] Assessing treatment effect heterogeneity in clinical trials with blocked binary outcomes
    Albert, JM
    Gadbury, GL
    Mascha, EJ
    BIOMETRICAL JOURNAL, 2005, 47 (05) : 662 - 673
  • [42] Elastic meta-analytic-predictive prior for dynamically borrowing information from historical data with application to biosimilar clinical trials
    Zhang, Wen
    Pan, Zhiying
    Yuan, Ying
    CONTEMPORARY CLINICAL TRIALS, 2021, 110
  • [43] Using historical control information for the design and analysis of clinical trials with overdispersed count data
    Gsteiger, Sandro
    Neuenschwander, Beat
    Mercier, Francois
    Schmidli, Heinz
    STATISTICS IN MEDICINE, 2013, 32 (21) : 3609 - 3622
  • [44] A generalized weighted combination test of treatment effect for clinical trials with a sequential parallel comparison design and binary endpoint
    Quan, Hui
    Chen, Xiaofei
    Luo, Junxiang
    Chen, Xun
    STATISTICS IN MEDICINE, 2022, 41 (15) : 2725 - 2744
  • [45] Information theory-based surrogate marker evaluation from several randomized clinical trials with binary endpoints, using SAS
    Tilahun, Abel
    Pryseley, Assam
    Alonso, Ariel
    Molenberghs, Geert
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2008, 18 (02) : 326 - 341
  • [46] Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: A tutorial
    Zohar, Sarah
    Teramukai, Satoshi
    Zhou, Yinghui
    CONTEMPORARY CLINICAL TRIALS, 2008, 29 (04) : 608 - 616
  • [47] Power and sample efficacy is required size for clinical trials when in multiple endpoints: application to an Alzheimer's treatment trial
    Xiong, CJ
    Yu, K
    Gao, F
    Yan, Y
    Zhang, ZJ
    CLINICAL TRIALS, 2005, 2 (05) : 387 - 393
  • [48] Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect
    Shan, Mu
    Guo, Beibei
    Liu, Hao
    Li, Qian
    Zang, Yong
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2023, 32 (05) : 885 - 894
  • [49] Design and analysis of clinical trials in the presence of delayed treatment effect
    Sit, Tony
    Liu, Mengling
    Shnaidman, Michael
    Ying, Zhiliang
    STATISTICS IN MEDICINE, 2016, 35 (11) : 1774 - 1779
  • [50] Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conferences
    Cornberg, Markus
    Lok, Anna Suk-Fong
    Terrault, Norah A.
    Zoulim, Fabien
    Berg, Thomas
    Brunetto, Maurizia R.
    Buchholz, Stephanie
    Buti, Maria
    Chan, Henry L. Y.
    Chang, Kyong-Mi
    Dandri, Maura
    Dusheiko, Geoffrey
    Feld, Jordan J.
    Ferrari, Carlo
    Ghany, Marc
    Janssen, Harry L. A.
    Kennedy, Patrick
    Lampertico, Pietro
    Liang, Jake
    Locarnini, Stephen
    Maini, Mala K.
    Mishra, Poonam
    Papatheodoridis, George
    Petersen, Joerg
    Schlottmann, Silke
    Wang, Su
    Wedemeyer, Heiner
    JOURNAL OF HEPATOLOGY, 2020, 72 (03) : 539 - 557